Axsome Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AXSM and other ETFs, options, and stocks.

About AXSM

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview.

CEO

Herriott Tabuteau

CEOHerriott Tabuteau

Employees

925

Employees925

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

2012

Founded2012

Employees

925

Employees925

AXSM Key Statistics

Market cap

11.41B

Market cap11.41B

Price-Earnings ratio

-59.65

Price-Earnings ratio-59.65

Dividend yield

—

Dividend yield—

Average volume

1.19M

Average volume1.19M

High today

$224.01

High today$224.01

Low today

$224.01

Low today$224.01

Open price

$225.00

Open price$225.00

Volume

131.00

Volume131.00

52 Week high

$234.29

52 Week high$234.29

52 Week low

$96.09

52 Week low$96.09

Stock Snapshot

Axsome Therapeutics(AXSM) stock is priced at $224.01, giving the company a market capitalization of 11.41B. It carries a P/E multiple of -59.65.

On 2026-05-06, Axsome Therapeutics(AXSM) stock traded between a low of $224.01 and a high of $224.01. Shares are currently priced at $224.01, which is 0.0% above the low and 0.0% below the high.

The Axsome Therapeutics(AXSM)'s current trading volume is 131, compared to an average daily volume of 1.19M.

During the past year, Axsome Therapeutics(AXSM) stock moved between $96.09 at its lowest and $234.29 at its peak.

AXSM News

TipRanks 1d

Axsome Therapeutics Earnings Call Signals Aggressive Growth

Axsome Therapeutics Inc. ((AXSM)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level dat...

TipRanks 2d

Axsome Therapeutics reports Q1 EPS ($1.26), consensus (86c)

Reports Q1 revenue $191.2M, consensus $190.69M. “Axsome had a tremendous start to 2026. Our commercial business delivered robust year-over-year growth in the fi...

Simply Wall St 3d

Axsome Therapeutics Is Up 11.1% After FDA Clears AUVELITY For Alzheimer’s Agitation Treatment

Axsome Therapeutics recently announced that the U.S. FDA has approved AUVELITY, a first-in-class oral NMDA receptor antagonist and sigma-1 agonist, to treat agi...

Analyst ratings

91%

of 22 ratings

Buy

90.9%

Hold

9.1%

Sell

People also own

Based on the portfolios of people who own AXSM. This list is generated using Robinhood data, and it’s not a recommendation.

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.